• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR XIERRO 2.5MM; STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR XIERRO 2.5MM; STENT Back to Search Results
Lot Number 1125250-38
Device Problem Partial Blockage (1065)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 12/04/2015
Event Type  Injury  
Event Description
Blockage in upper ground and coronary blockage.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
XIERRO 2.5MM
Type of Device
STENT
Manufacturer (Section D)
ABBOTT VASCULAR
MDR Report Key6446151
MDR Text Key71457557
Report NumberMW5068736
Device Sequence Number1
Product Code NIQ
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other
Type of Report Initial
Report Date 02/22/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/28/2017
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Lot Number1125250-38
Other Device ID Number5082841
Was Device Available for Evaluation? Yes
Was Device Evaluated by Manufacturer? No Information
Type of Device Usage N
Patient Sequence Number1
Treatment
AMLODIPINE 5 MG TABLET; ASPIRIN 81 MG CHEWABLE TABLET; ATORVASTATIN 40 MG TABLET. ; FIORICET 50 - 300 - 40 MG CAPSULE; HYDROCODONE/ ACETAMINOEA 5-325 TABLET; LISINOPRIL 5 MG TABLET; METOPROLOL SUCCINATE 25 G 24 HOURS; NAPROXEN 500 MG TABLETS; NIRTROGLYCERIN 0.4 MG SUBLINGUAL TABLET; RX MEDS: ALPRA2 0.5 MG TABLET; TIZANIDINE 4 MG TABLET
Patient Outcome(s) Hospitalization;
-
-